tirzepatide in vial Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity 1 and GIP therapy Tirzepatide Flex-Dose 1 mL Injectable

Yes, when administered by a trained provider using pharmaceutical-grade compounds

Contact your GP or diabetes nurse immediately if you experience: Severe, persistent abdominal pain, particularly if accompanied by back pain and/or vomiting (potential pancreatitis warning) stop taking Trulicity and seek urgent medical attention Persistent vomiting preventing adequate fluid intake Signs of dehydration (dark urine, dizziness, reduced urination) which could affect kidney function Symptoms that do not improve after 46 weeks of treatment Rarely, Trulicity may cause more serious adverse effects including pancreatitis, gallbladder problems, or hypoglycaemia

Some of the research, including this 2025 review, indicates that it may reduce headache frequency, severity, and intensity, but again, more research is needed to confirm the appropriate dosage

Diabetologia 49 , 289297 (2006)

doi: 10.1016/j.gene.2023.148055 136